Carcinoembryonic Antigen (CEA) Market Sales Forecasts Reveal Positive Growth Through 2027

Valley Cottage, NY -- (SBWIRE) -- 08/07/2019 -- Carcinoembryonic antigen (CEA) is normally found in embryonic entodermal epithelium. Carcinoembryonic antigen is a group of glycoprotein present in the body fluids of the fetus and embryo and in the gastrointestinal tract. Carcinoembryonic antigen is also present in the mucosal cells of the colorectum, gastrointestinal cells, and small amounts are present in the blood. Carcinoembryonic antigen is produced by the gastrointestinal tissues during the development of fetal. CEA is not present in the healthy adults but cancer patients show concentrations of CEA. A carcinoembryonic antigen test is generally a blood test that measures the amount of carcinoembryonic antigen protein in the blood. The test is also used to manage and diagnose certain types of cancers like breast cancer, colorectal or colon cancer, cancer of the gastrointestinal tract, liver cancer, ovarian cancer, lung cancer and others. The sensitivity of carcinoembryonic antigen is low for early colon cancer patients. The Carcinoembryonic antigen (CEA) test is especially used for cancers of the rectum and large intestine. Carcinoembryonic antigen is one of the most commonly used tumor markers globally. But its primary significance is in colorectal cancer.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.